These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27235189)

  • 21. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis.
    Rivas-Santiago B; Rivas Santiago CE; Castañeda-Delgado JE; León-Contreras JC; Hancock RE; Hernandez-Pando R
    Int J Antimicrob Agents; 2013 Feb; 41(2):143-8. PubMed ID: 23141114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Antimicrobial Peptides in Treatment and Prevention of Mycobacterium Tuberculosis: A Review.
    Mehta K; Sharma P; Mujawar S; Vyas A
    Int J Pept Res Ther; 2022; 28(5):132. PubMed ID: 35891800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
    Sharma A; Khuller GK; Sharma S
    Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
    Xu Z; Gao C; Ren QC; Song XF; Feng LS; Lv ZS
    Eur J Med Chem; 2017 Oct; 139():429-440. PubMed ID: 28818767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repurposed drug candidates for antituberculosis therapy.
    An Q; Li C; Chen Y; Deng Y; Yang T; Luo Y
    Eur J Med Chem; 2020 Apr; 192():112175. PubMed ID: 32126450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural antimicrobial peptides against Mycobacterium tuberculosis.
    Abedinzadeh M; Gaeini M; Sardari S
    J Antimicrob Chemother; 2015 May; 70(5):1285-9. PubMed ID: 25681127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycothiol: a promising antitubercular target.
    Nilewar SS; Kathiravan MK
    Bioorg Chem; 2014 Feb; 52():62-8. PubMed ID: 24368170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tubercular peptides: A quest of future therapeutic weapon to combat tuberculosis.
    Khusro A; Aarti C; Agastian P
    Asian Pac J Trop Med; 2016 Nov; 9(11):1023-1034. PubMed ID: 27890360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis.
    Zhang YJ; Li XJ; Mi KX
    Yi Chuan; 2016 Oct; 38(10):918-927. PubMed ID: 27806933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of antimicrobial peptide with mycolyl transferase in Mycobacterium tuberculosis.
    Banerjee DI; Gohil TP
    Int J Mycobacteriol; 2016 Mar; 5(1):83-8. PubMed ID: 26927995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent progress on pyrazole scaffold-based antimycobacterial agents.
    Keri RS; Chand K; Ramakrishnappa T; Nagaraja BM
    Arch Pharm (Weinheim); 2015 May; 348(5):299-314. PubMed ID: 25820461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES; Mallampalli A
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New tuberculosis therapeutics: a growing pipeline.
    Spigelman MK
    J Infect Dis; 2007 Aug; 196 Suppl 1():S28-34. PubMed ID: 17624823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
    Hudson SA; McLean KJ; Munro AW; Abell C
    Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.